EDC 9

Drug Profile

EDC 9

Alternative Names: EDC-9

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Centrose
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diffuse large B cell lymphoma

Highest Development Phases

  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 25 Jul 2016 EDC 9 is available for licensing as of 25 Jul 2016. http://www.centrosepharma.com/
  • 16 Apr 2016 Preclinical trials in Diffuse large B cell lymphoma in USA (Parenteral) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top